Compare Crispr Therapeutics AG (CRSP) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Core MSCI Emerging Markets ETF — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 33.2× Crispr Therapeutics AG's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares Core MSCI Emerging Markets ETF for 57 Days on average.
| CRSP | IEMG | |
|---|---|---|
Market Cap | $4.88B | $162.00B |
Volume | 2,861,747 | 13,446,151 |
Sector | Health | Broad Market / Factor |
52-Week High | $73.97 | $86.00 |
52-Week Low | $44.34 | $64.22 |
Typical Hold Time | 77 Days | 57 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
IEMG is trading at $80.5, down 1.88% over the past 24 hours amid a bearish technical signal. The ETF's technical indicators show selling pressure with moving averages signaling bearish momentum, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers, with the fund delivering 35% returns over the past year according to Fool - Investing News on 2026-07-06, though it faces higher volatility than broader international alternatives.
The outlook for IEMG remains mixed with technical weakness offset by strong recent performance in emerging markets. Key risks include concentration in technology sectors (39% weighting) and higher volatility compared to developed market ETFs. Analyst comparisons favor IEMG for emerging market exposure but note cost disadvantages versus competitors like SCHE with its 0.03% expense ratio versus IEMG's 0.09%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
